| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642641P | 2018-03-14 | 2018-03-14 | |
| US201862683720P | 2018-06-12 | 2018-06-12 | |
| US201862699274P | 2018-07-17 | 2018-07-17 | |
| US201862729518P | 2018-09-11 | 2018-09-11 |
| Publication Number | Publication Date |
|---|---|
| CL2020002342A1true CL2020002342A1 (en) | 2020-12-18 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002342ACL2020002342A1 (en) | 2018-03-14 | 2020-09-10 | Use of anti-il-36r antibodies for the treatment of generalized pustular psoriasis |
| Country | Link |
|---|---|
| US (2) | US20190284285A1 (en) |
| EP (1) | EP3765513A1 (en) |
| JP (2) | JP7404256B2 (en) |
| KR (1) | KR102768040B1 (en) |
| CN (1) | CN112272674A (en) |
| AU (1) | AU2019236105B2 (en) |
| BR (1) | BR112020016738A2 (en) |
| CA (1) | CA3093692A1 (en) |
| CL (1) | CL2020002342A1 (en) |
| IL (1) | IL277215B1 (en) |
| MX (1) | MX2020009544A (en) |
| PH (1) | PH12020551444A1 (en) |
| WO (1) | WO2019177888A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016168542A1 (en) | 2015-04-15 | 2016-10-20 | Anaptysbio, Inc. | Antibodies directed against interleukin 36 receptor (il-36r) |
| MA47106A (en) | 2016-12-21 | 2019-10-30 | Amgen Inc | ANTI-TNF ALPHA ANTIBODY FORMULATIONS |
| SG11202012360YA (en) | 2018-07-16 | 2021-01-28 | Regeneron Pharma | Anti-il36r antibodies |
| CA3124996A1 (en)* | 2018-12-27 | 2020-07-02 | Boehringer Ingelheim International Gmbh | Il-36r antibodies for treatment of palmoplantar pustulosis |
| MX2021010783A (en) | 2019-03-08 | 2021-09-30 | Boehringer Ingelheim Int | ANTI-IL-36R ANTIBODY FORMULATIONS. |
| JP2023534955A (en) | 2020-07-17 | 2023-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Anti-IL-36R antibody for treatment of neutrophilic dermatosis |
| WO2022026829A1 (en)* | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity |
| EP4188441A1 (en)* | 2020-07-30 | 2023-06-07 | AnaptysBio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis |
| CN112180007B (en)* | 2020-09-16 | 2023-08-18 | 上海市皮肤病医院 | Metabonomics-based diagnosis marker for generalized pustular psoriasis and application thereof |
| WO2022072267A1 (en)* | 2020-09-30 | 2022-04-07 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibodies for treatment of chronic inflammatory pain |
| CN114907477A (en)* | 2021-02-08 | 2022-08-16 | 上海普铭生物科技有限公司 | Anti-human IL-36R antibodies and uses thereof |
| US20220281987A1 (en)* | 2021-03-04 | 2022-09-08 | Boehringer Ingelheim International Gmbh | Methods for the treatment of gpp |
| WO2022192531A2 (en)* | 2021-03-12 | 2022-09-15 | Boehringer Ingelheim International Gmbh | Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis |
| CN117615788A (en)* | 2021-05-12 | 2024-02-27 | 安奈普泰斯生物有限公司 | Antibody compositions |
| CN113274494B (en)* | 2021-06-07 | 2022-09-20 | 武汉生物制品研究所有限责任公司 | Liquid preparation of recombinant fully human monoclonal antibody for resisting SARS-CoV-2 |
| CN115327130A (en)* | 2022-07-25 | 2022-11-11 | 深圳市妇幼保健院 | Application of immune biomarker in preparation of pediatric sepsis diagnostic kit |
| CN115724975A (en)* | 2022-10-20 | 2023-03-03 | 江苏荃信生物医药股份有限公司 | Human interleukin 36receptor monoclonal antibody and application thereof |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US20090270480A1 (en)* | 2005-12-28 | 2009-10-29 | Bernard Amegadzie | Markers and Methods for Assessing and Treating Psoriasis and Related Disorders |
| WO2009040602A1 (en) | 2007-09-25 | 2009-04-02 | Becton Dickinson France | Autoinject0r with deactivating means moveable by a safety shield |
| DK2780373T3 (en)* | 2011-11-16 | 2019-11-04 | Boehringer Ingelheim Int | Anti-IL-36R antibodies |
| CH705992A2 (en) | 2012-10-11 | 2013-06-14 | Tecpharma Licensing Ag | Injection device for injecting e.g. liquid medication to tissue, has trigger unit that is movable in relation to housing to cause holding sleeve to release drive unit such that drive unit is triggered by distal movement of trigger unit |
| WO2015022656A1 (en)* | 2013-08-15 | 2015-02-19 | Novartis Ag | Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists |
| WO2016168542A1 (en)* | 2015-04-15 | 2016-10-20 | Anaptysbio, Inc. | Antibodies directed against interleukin 36 receptor (il-36r) |
| EP3285831B1 (en) | 2015-04-24 | 2024-05-01 | SHL Medical AG | Sub-assembly of a medicament delivery device and a medicament delivery device |
| CH711066A2 (en) | 2015-05-13 | 2016-11-15 | Tecpharma Licensing Ag | Improved injection device. |
| JP2020512344A (en)* | 2017-03-27 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Anti-IL-36R antibody combination treatment |
| Publication number | Publication date |
|---|---|
| KR20200131871A (en) | 2020-11-24 |
| AU2019236105A1 (en) | 2020-08-27 |
| IL277215B1 (en) | 2025-06-01 |
| IL277215A (en) | 2020-10-29 |
| JP7673168B2 (en) | 2025-05-08 |
| EP3765513A1 (en) | 2021-01-20 |
| KR102768040B1 (en) | 2025-02-17 |
| CN112272674A (en) | 2021-01-26 |
| CA3093692A1 (en) | 2019-09-19 |
| WO2019177888A1 (en) | 2019-09-19 |
| AU2019236105B2 (en) | 2025-07-31 |
| MX2020009544A (en) | 2020-10-05 |
| US20210087285A1 (en) | 2021-03-25 |
| JP7404256B2 (en) | 2023-12-25 |
| PH12020551444A1 (en) | 2021-08-23 |
| US20190284285A1 (en) | 2019-09-19 |
| JP2021517566A (en) | 2021-07-26 |
| BR112020016738A2 (en) | 2020-12-15 |
| JP2024028951A (en) | 2024-03-05 |
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002342A1 (en) | Use of anti-il-36r antibodies for the treatment of generalized pustular psoriasis | |
| CL2019002824A1 (en) | Anti-lag3 antibodies. | |
| CL2019001874A1 (en) | Context-permissive isoform-specific tgfß1 inhibitors and their use. | |
| CL2021001179A1 (en) | Antibodies specific for tl1a and nucleic acids encoding them (divisional of application no. 201801596). | |
| CL2021000716A1 (en) | Antibody constructs for flt3 and cd3. (divisional sol. 201800269) | |
| CL2020001048A1 (en) | Monoclonal antibodies against bcma. (divisional request 201800281) | |
| CL2018001790A1 (en) | Processes to prepare a jak1 inhibitor and new forms of this (divisional application 201602748) | |
| CL2021001685A1 (en) | Anti-il-36r antibodies for the treatment of palmoplantar pustulosis | |
| CL2021001430A1 (en) | Glp-1 compositions and their uses. (request divisional 202000422) | |
| CO2022009696A2 (en) | Anti-lilrb1 antibody and uses thereof | |
| UY39135A (en) | HUMAN MONOCLONAL ANTIBODIES TARGETED AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) | |
| MX2024006565A (en) | PRO/LATENT ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE THEREOF. | |
| CR20200483A (en) | Anti-hla-g antibodies and use thereof | |
| JOP20190194B1 (en) | Cyclic di-nucleotides compounds for the treatment of cancer | |
| CL2021003353A1 (en) | Joint antineoplastic treatment. | |
| ECSP16061758A (en) | GPR6 TETRAHYDROPYRIDOPYRAZINE MODULATORS | |
| MX2015012872A (en) | ANTI-TAU ANTIBODIES AND METHODS OF USE. | |
| MX2017010667A (en) | Anti-pvrig antibodies and methods of use. | |
| CR20160199A (en) | COMBINED THERAPY WITH AN ANTI-ANG2 ANTIBODY AND A CD40 AGONIST | |
| CL2021003422A1 (en) | Anti-il-13ra2 antibodies and uses thereof (divisional 201902323). | |
| MX2018005070A (en) | COMPOSITION FOR THE TREATMENT OF CANCER WITH EXPRESSION OF IGF-1R. | |
| MX2017007829A (en) | An antimicrobial composition. | |
| CL2021003373A1 (en) | New egfr inhibitors | |
| CO2021000092A2 (en) | Antibodies comprising a polypeptide inserted into framework region 3 | |
| BR112017022281A2 (en) | methods to treat cancer |